A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)
A Randomised Phase 2 Trial of Pemetrexed and Gefitinib Versus Gefitinib as First Line Treatment for Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
Sponsor: Eli Lilly and Company
Listed as NCT01469000, this PHASE2 trial focuses on Carcinoma, Non Small Cell Lung and remains completed. Sponsored by Eli Lilly and Company, it has been updated 10 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
May 2019 — Oct 2019 [monthly]
Completed PHASE2
-
Jun 2018 — May 2019 [monthly]
Completed PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Feb 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aichi, Japan , Beijing, China , Changchun, China , Changsha, China , Cheong Ju-City, South Korea , Chiba, Japan , Guangzhou, China , Hyōgo, Japan , Incheon, South Korea , Kanagawa, Japan and 15 more locations